Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:32:09.760Z.
Calculation as of: 2026-10-06T17:32:09.760Z.
Quote observation: 2026-10-06T17:28:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0d034b685c23fadaea9476ccc197406393d04780d3c67e2351ab6b6412cf62fb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Fractyl Health, Inc.
Market Cap
$61.08M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Fractyl Health, Inc. (GUTS) | $61.08M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.19M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.43M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.64M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.76M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.09M | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $61.35M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.17M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.40M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
